Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
CAMBRIDGE, Mass., Aug. 24, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management will present at the following upcoming investor conferences.
- Baird 2017 Global Healthcare Conference on September 7, 2017 at 11:25 a.m. ET. The fireside chat will be held at the InterContinental New York Barclay Hotel in New York.
- Morgan Stanley 2017 Global Healthcare Conference on September 11, 2017 at 10:30 a.m. ET. The fireside chat will be held at the Grand Hyatt Hotel in New York.
- LEERINK Partners Roundtable – Rare Disease on September 27, 2017 at 10:00 a.m. ET. The fireside chat will be held at the Lotte New York Palace Hotel in New York.
The presentations will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
